UK researchers have received £2.1m (NZ$4.36m) to develop a soft contact lens (CL) that can repair eye damage by transferring corneal epithelial cells directly to the ocular surface of the eye.
A novel 3D tactile label for drop bottles, designed to increase the accurate identification of medication and improve compliance in low vision patients, was correctly ‘read’ by 92% of test patients in
Attracting attention on Optimed’s stand from paediatric ophthalmologists and ophthalmic nurses was NeoLight’s Icon retinal imaging system, designed specifically to screen premature babies both in large hospital settings and in more remote areas.
Eye Health Aotearoa (EHA) will run a nationwide New Zealand Children’s Eye Health Campaign in September, finishing on World Sight Day on 10 October 2024.
A Chinese research team has developed a new ‘smart’ contact lens (CL) that can continuously monitor intraocular pressure (IOP), regardless of environmental temperature fluctuations. Led by Dengbao X
In an ocean of technical advances, a one-stop software shop, offering a fully customised, device-agnostic practice management system to ophthalmology clinics, was described as a technology breakthrough at RANZCO 2024. “GoodX brings a different software package to New Zealand, which no one else seems
US researchers have found that deleting a gene in mice reduced the subretinal fibrosis associated with nAMD, indicating a new therapeutic target to treat the nearly two-thirds of nAMD patients for whom anti-VEGF treatment is ineffective.
Preliminary results of a clinical trial of MyopiaX, a low-level laser device to treat progressive myopia in children, showed it was safe and tolerable and produced proof-of-concept data, reported its German developer Dopavision.
The authors of a University of Auckland study investigating the safety of UVC light to treat microbial keratitis said evidence of DNA damage was limited to the superficial epithelium. The study, led
University of East Anglia (UEA) researchers have made a breakthrough in ocular device technology with the introduction of a novel resin to 3D-print intraocular lenses (IOLs), potentially offering cheaper, faster manufacturing and more customisation.
Interim results from the ongoing phase 2 Australian trial of darovasertib, an oral neoadjuvant/adjuvant uveal melanoma (UM) treatment, showed 75% of treated patients were spared enucleation, reported the drug’s US developer, Ideaya Biosciences.
New to this part of the world, Vitrocap N is a nutritional supplement that’s been specially formulated for eye floaters...
